Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove

Medicine

A Proinflammatory, Degenerative Organ Culture Model to Simulate Early-Stage Intervertebral Disc Disease.

doi: 10.3791/62100 Published: February 14, 2021
* These authors contributed equally

Summary

This protocol presents a novel experimental model of proinflammatory, degenerative bovine organ culture to simulate early-stage intervertebral disc degeneration.

Abstract

Symptomatic intervertebral disc (IVD) degeneration (IDD) is a major socioeconomic burden and is characterized by inflammation and tissue degradation. Due to the lack of causative therapies, there is an urgent need for innovative experimental organ culture models to study the mechanisms involved in the progression of the disease, find therapeutic targets, and reduce the need for animal models. We here present a novel, three-dimensional organ culture model protocol mimicking the proinflammatory and catabolic microenvironment, which is present during IDD.

Initially, bovine caudal IVDs were dissected, cleaned, and cultured in the tissue culture medium. Dynamic physiologic or pathologic loading was applied in a custom-made bioreactor for 2 hours per day. IVDs were assigned to a control group (high glucose medium, physiological loading, phosphate-buffered saline injection) and a pathological group (low glucose medium, pathological loading, tumor necrosis factor-alpha injection) for four days. Gene expression analysis from collected nucleus pulposus cells of the IVDs and enzyme-linked immunosorbent assay of the conditioned organ culture media was performed.

Our data revealed a higher expression of inflammatory markers and reduced disc heights after loading in the pathological group compared to the control group. This protocol is reliable to simulate IVD inflammation and degeneration and can be further expanded to broaden its application scope.

Introduction

or Start trial to access full content. Learn more about your institution’s access to JoVE content here

Low back pain (LBP) can affect individuals of all ages and is a leading cause for disability worldwide1,2,3. The total cost associated with LBP exceeds $100 billion per year4,5. Symptomatic intervertebral disc (IVD) degeneration (IDD), a condition characterized by inflammation and tissue degradation, is a major cause of LBP6,7. Specifically, IDD is characterized by a gradually evolving breakdown of the IVD's extracellular matrix (ECM), induced and triggered by multiple factors that lead to an accelerated pathology, neurological disorders, and eventually disability. Furthermore, IDD is associated with the release of proinflammatory cytokines, altered spine biomechanics, angiogenesis, and nerve ingrowth, which increases pain sensation, altogether causing chronic LBP (active discopathy)6,8. To date, treatment options include discectomy and subsequent fusion of the adjacent vertebrae, implantation of an IVD prosthesis, or non-surgical approaches, such as non-steroidal anti-inflammatory drugs, opioids, and muscle relaxants for patients with IDD9. Both current standard therapeutic options, surgical and non-surgical, are only partly effective and fail to address the underlying biological problem9,10. Early-stage degenerative disc disease is characterized by an initial inflammatory tissue response, especially an increase in tumor necrosis factor-alpha (TNF-alpha) expression11. These early disc changes primarily occur at the cellular level without disrupting the disc architecture and could previously be mimicked by nutritional deficiency under pro-inflammatory conditions12. Therefore, precise simulation of the in vivo situation to investigate these degeneration mechanisms and find suitable therapeutic targets is crucial. Additionally, to these simulations of molecular properties, the mechanical loading environment of the discs plays a key role in pathological and physiological changes of IVD. Consequently, combining these approaches would bring us one step forward to mimic the complex microenvironment of IVDs in vivo. There are currently no studies considering the aspect of dynamic loading along with the pro-inflammatory and nutritional setting to the best of our knowledge.

Although large animal models allow the investigation of potential relevant in vivo interactions, they are costly and work intensive. Moreover, as the use of animal models in research has long been a matter of controversy, the reduction of the number of animals needed to answer important research questions is of great interest. Finally, there is currently no ideal animal model to mimic IDD in IVD research13,14. Therefore, it is necessary to establish a cost-effective and reliable replacement, such as an organ culture model to simulate IDD and associated inflammatory and degenerative processes. Recently, the application of the present protocol on the establishment of a proinflammatory and degenerative organ culture model to simulate early-stage intervertebral disc disease allowed us to investigate the effect of anti-inflammatory drugs in the IDD organ culture15.

Here, we describe how to obtain bovine intervertebral discs and induce the state of early-stage IDD via a catabolic and proinflammatory microenvironment caused by direct intradiscal injection of tumor necrosis factor-alpha (TNF-α) and degenerative loading in a bioreactor under low nutritive medium conditions. Figure 1 illustrates the experimental model and shows the bioreactor used to simulate degenerative and physiological loading conditions.

Figure 1
Figure 1: Illustration of the experimental setup. A: bovine tail; B: dissected bovine intervertebral discs; C: transfer of the disc to a well-plate with culture medium; D: loading the simulation in a bioreactor; E: intradiscal injection technique; F: IVD after injection of PBS/trypan blue dye to reveal distribution. IDD: intervertebral disc degeneration. Please click here to view a larger version of this figure.

Subscription Required. Please recommend JoVE to your librarian.

Protocol

or Start trial to access full content. Learn more about your institution’s access to JoVE content here

Experiments were performed using bovine tails obtained from local abattoirs. The biological materials used in the current study are taken from the food chain and require no ethical approval in Swiss and European law.

1. Dissection of the bovine intervertebral disc

  1. Rinse the whole tail thoroughly with tap water to remove dirt and hair on the surface.
    NOTE: With intact, distal ends, a maximum of 9 IVDs (coccygeal 1-9) per tail can be used for the experiments depending on the desired size of the IVDs. Considering the desired diameter between 15-20 mm, we used 12 bovine tails with 5 IVDs per tail for the experiments.
  2. Immerse the whole tail in a box containing 1% betadine solution for 10 min. Briefly dry the tail with sterile gauze and place it on a sterile drape.
    NOTE: During dissection of the disc, humidify the tails with Ringer's solution wetted gauze to prevent dehydration. Store the tails (or left-over segments) wrapped in wet gauze until the whole dissection procedure is completed.
  3. Use a scalpel (No. 20) to remove the soft tissue as completely as possible from the caudal spine to facilitate the identification of the IVDs. Remove the spinous and transverse processes of the vertebrae with bone removal pliers.
    NOTE: Select IVDs with the desired diameter. IVDs with a diameter range of 15-20 mm were used in the current study.
  4. Cut transversely with bone pliers through the middle of each vertebral body to obtain individual motion segments. Put motion segments in a Petri dish with gauze wetted with Ringer's solution.
  5. Locate the IVD and vertebra by palpation and by moving the motion segments gently. Make two parallel cuts with the band saw in the growth plate of the IVDs, one on each side of the IVD. Identify the location of the growth plate by touching and finding the convex site of the bony endplate part (hard) adjacent to the disc (soft) with a safety distance of approximately 0.5-1 mm from the IVD towards the vertebra. Ensure that the blade of the band saw is cooled with Ringer's solution while cutting the vertebrae.
  6. Transfer IVDs in a clean Petri dish with clean gauze wetted with Ringer's solution.
    NOTE: The gauze should be moistened and not too wet to prevent swelling of the IVDs,
  7. Use the scalpel blade to scrape off the vertebral body (red/pink bone), growth plate (white cartilage), leave the endplate intact (yellow-pink). Make the two surfaces flat and parallel for the loading procedure. Transfer scraped IVDs to a fresh Petri dish with gauze wetted with Ringer's solution.
    NOTE: Wear a chainmail glove to protect the hand while holding the IVD and scraping.
  8. Measure the disc height and diameter with a caliper. Clean the blood clots in the vertebrae bone with Ringer's solution using a jet lavage system.
  9. Transfer the IVDs to 50 mL plastic tubes, one IVD per tube. Add 25 mL of Phosphate-Buffered Saline (PBS) + 10% Penicillin/Streptomycin (P/S) per IVD and leave it shaking for 15 min on an orbital shaker at room temperature.
  10. Aspirate the supernatant and add 10 mL of PBS + 1% P/S per IVD for 2 min to rinse the IVDs.

2. IVD culture and loading

  1. Transfer discs to IVD chambers and add IVD culture medium (Dulbecco's Modified Eagle Medium (DMEM, 4.5 g/L high glucose DMEM for the physiological group and 2 g/L low glucose DMEM for the pathological group) + 1% P/S + 2% fetal calf serum + 1% ITS (contains 5 µg/mL insulin, 6 µg/mL transferrin, and 5 ng/mL selenious acid) + 50 µg/mL ascorbate-2-phosphate + 1% non-essential amino acid + 50 µg/mL antimicrobial agent for primary cells) and place in an incubator at 37 °C, 85% humidity and 5% CO2.
  2. Culture the discs for 4 days within a bioreactor system according to experimental groups16. In the pathologic group, maintain degenerative loading conditions at 0.32-0.5 MPa, 5 Hz for 2 h/day. In the physiological control group, use a loading protocol of 0.02-0.2 MPa, 0.2 Hz for 2 h/day.
    NOTE: Position the IVDs in chambers containing 5 mL of IVD medium during the loading procedures. The volume depends on the size of the bioreactor's loading chambers. Between the loading procedures, place the IVDs in six-well plates with 7 mL of IVD culture medium for free-swelling recovery.
  3. For analyzing the changes in disc height during the experimental period, measure the disc height with a caliper after IVD dissection (baseline) and then daily after the free swelling period and after dynamic loading for the experimental duration.

3. Intradiscal tumor necrosis factor-alpha (TNF-α) injection

  1. Directly after the first dynamic loading cycle on day 1, place the IVDs in a Petri dish in a vertical position and stabilize the IVDs with a tweezer.
  2. Inject recombinant TNF-α (100 ng in 70 µL of PBS per IVD) with a 30-gauge insulin needle into the nucleus pulposus tissue of the pathological group17. Inject slowly at a speed of approximately 70 µL in 1 min.
  3. After injection, pull the syringe halfway back within the IVD and pull the syringe plunger to create a vacuum that prevents the injected solution from leaking back, before removing the needle and syringe completely from the IVD.
    ​NOTE: Perform a pilot experiment by injecting PBS containing trypan blue dye to evaluate the distribution of the injected solution after loading and overnight culture.

4. Gene expression

  1. Harvest the IVDs on day 4. Collect the nucleus pulposus (NP) tissue (gelly part in the middle of IVD) with a biopsy punch. Collect the outer annulus fibrosus (AF) with a scalpel blade (No.20).
    NOTE: For the baseline reference at day 0, collect tissues immediately after dissection for RNA extraction.
  2. Use the amount of NP or AF tissue needed for gene expression analysis, depending on the experimental design.
    NOTE: For the present experiments, approximately 150 mg tissue was used. The ratio of RNA isolation solution to tissue mass should be at least 2 mL per 100-150 mg tissue for efficient extraction.
  3. Digest the NP or AF tissue with the digestion solution (0.2% pronase in DMEM, filter sterilized) and incubate for 1 h at 37 °C with magnetic stirring18.
  4. Flash-freeze the tissue samples using liquid nitrogen and pulverize to a fine powder. Divide the pulverized tissue powder equally into two 2 mL tubes each containing 1 mL of guanidine thiocyanate and phenol in a monophase solution (RNA isolation solution).
  5. Perform the homogenization in 2 mL tubes containing the RNA isolation solution and the pulverized tissue powder. Homogenize the tissue powder 5x with an 8 mm stainless steel ball and a tissue-lyzer at 30 Hz for 3 min. Centrifuge at 12,000 x g, 4 °C for 10 min and transfer the supernatant to a fresh tube. The supernatants can be stored at -80 °C for at least one month.
  6. Add 0.1 mL of 1-bromo-3-chloropropane (BCP) per 1 mL of RNA isolation solution and shake vigorously for 15 s. Store the resulting mixture at room temperature on an orbital shaker for 15 min and centrifuge at 12,000 x g for 15 min at 4 °C.
    NOTE: The RNA remains exclusively in the upper aqueous phase.
  7. Transfer the aqueous phase into a fresh tube and precipitate RNA with 0.25 mL of isopropanol and 0.25 mL of high salt precipitation solution per 1 mL of RNA isolation solution used for initial homogenization. Store the samples at room temperature for 15 min on an orbital shaker and centrifuge at 12,000 x g for 8 min at 4 °C.
    ​NOTE: Alternatively, use the column-based RNA extraction method which generally leads to higher RNA purity but lower RNA yield.
  8. Remove the supernatant and wash the RNA pellet with 1 mL of 75% ethanol per 1 mL of RNA isolation solution used for initial homogenization. Centrifuge at 7,500 x g for 5 min at 4 °C.
  9. Remove the ethanol wash and briefly air-dry RNA pellet for 3-5 min. Dissolve the RNA in 20 µL of diethylpyrocarbonate (DEPC) treated water by passing the solution a few times through a pipette tip and incubating for 10-15 min at 55-60 °C.
  10. Measure the absorbance at 230 nm, 260 nm, and 280 nm (A230, A260 and A280 respectively). A260 of 1.0 corresponds to 40 µg/mL RNA. An A260/A280 ratio of 1.6-1.9 is expected, whereas contamination results in a A260/A280 ratio of <1.6.
  11. Prepare a reverse transcriptase (RT) reaction mix for a 20 µL reaction volume. The mix contains RT enzyme mix, ribonuclease inhibitor, helper protein, primers, dNTPs, MgCl2, RNase free water, and 0.4 μg of RNA sample.
  12. Briefly centrifuge the RT tubes to mix all the components at the bottom of the tube.
  13. Place the samples in the thermocycler instrument. Select the appropriate program for the RT. Run the RT for 10 min at 25 °C, followed by the reverse transcription step for 120 min at 42 °C and inactivation of the reverse transcriptase for 5 min at 85 °C, cooling it down to 4 °C at the end.
  14. Dilute the resulting cDNA with Tris(hydroxymethyl)aminomethane (Tris)-ethylenediaminetetraacetic acid (EDTA) (TE) buffer (10 mM Tris with 1 mM EDTA) to a final concentration of 0.4 µg RNA used for RT per 100 µL cDNA solution. Store the cDNA samples at -20 °C.
  15. Perform real-time polymerase chain reaction (PCR) using a 10 µL reaction volume. The reaction volume contains the master mix (containing DNA polymerase, uracil-DNA glycosylase, dNTPs with dUTP, passive reference and optimized buffer components), forward primer 45 µM, reverse primer 45 µM, probe 12.5 µM (containing a reporter dye linked to the 5' end of the probe, a minor groove binder at the 3' end of the probe, and a nonfluorescent quencher at the 3' end of the probe), 2 µL cDNA and DEPC-treated water.
  16. Run an endogenous control (RPLP0) for relative quantification with the 2-ΔΔCT method19.
  17. Add samples in duplicates and run a no template control by adding TE-buffer instead of cDNA. Run PCR at standard conditions (2 min at 50 °C, 10 min at 95 °C, 40 cycles of 15 s at 95 °C, and 1 min at 60 °C).
  18. Perform relative quantification of mRNA targets following the comparative CT method. The amount of mRNA normalized to the baseline sample is calculated as 2-ΔΔCT, whereas ΔΔCT is the difference between the ΔCT (CT target- CT endogenous control) of sample and ΔCT (CT target and CT endogenous control) of the baseline sample.

5. Quantification of protein content in the IVD medium

  1. Collect the medium conditioned by the IVD samples to measure the protein content in the medium. Perform enzyme-linked immunosorbent assay (ELISA) according to the protocol of the target protein.
  2. Bovine interleukine-8 (IL-8) is quantified by anti-bovine IL8 ELISA kit according to the manufacturer's instruction.

Subscription Required. Please recommend JoVE to your librarian.

Representative Results

or Start trial to access full content. Learn more about your institution’s access to JoVE content here

Degenerative loading in low glucose medium combined with TNF-α injection caused a significant increase of the gene expression of proinflammatory markers interleukin 6 (IL-6) and interleukin 8 (IL-8) compared to the physiological control group in NP cells after 4 days of culture (Figure 2). In contrast, we did not observe significant changes for the proinflammatory genes interleukin 1β (IL-1β) and TNF-α in NP cells (data not shown). Furthermore, degenerative culture conditions did not alter the gene expression of IL-6 and IL-8 in AF cells.

Figure 2
Figure 2: Gene expression levels in the nucleus pulposus (NP) tissue and annulus fibrosus (AF) tissues. These were measured after 4 days of culture under physiological or pathological culture condition, normalized to baseline (day 0). Means ± 95% confidence interval n=8, **p<0.01. This figure has been modified from20. Please click here to view a larger version of this figure.

Consistent with the gene expression findings, the IL-8 protein content in the medium showed a marked increase after 2 days and 4 days compared to the physiological condition (Figure 3). However, the measurements at day 3 (after free-swelling or loading) revealed no significant differences between the study groups, although the results indicated higher values for the degenerative group.

Figure 3
Figure 3: Quantification of the pro-inflammatory protein IL-8 release in the IVD culture medium after free swelling culture (FS) and dynamic loading (Load). The results are shown as the original concentrations in ng/mL in the medium without normalization. Mean ± 95% confidence interval, n=8, **p<0.01. This figure has been modified from20. Please click here to view a larger version of this figure.

The disc height (DH) changes normalized to the DH after dissection are shown in Figure 4. Whereas DH reductions after loading revealed higher values (i.e., more height reduction) for the degenerative group compared to the physiological groups, no differences in disc height gains after the free-swelling period were seen between the study groups. This indicated that the difference in disc height changes between the pathological and physiological group was higher after the loading procedure. Furthermore, the differences were less pronounced after 1 day compared to the measurements on days 2 and 3, indicating a progressive effect of the degenerative and inflammatory conditions.

Figure 4
Figure 4: Disc height changes normalized to the baseline values (after dissection). Mean ± 95% confidence interval. FS: free-swelling. N=10, ***p<0.001. This figure has been modified from20. Please click here to view a larger version of this figure.

Subscription Required. Please recommend JoVE to your librarian.

Discussion

or Start trial to access full content. Learn more about your institution’s access to JoVE content here

We here provided a detailed protocol to simulate degenerative and inflammatory IVDD. This protocol can be applied for detailed examinations of inflammatory pathways leading to the destructive effects on the disc. Moreover, the protocol can help to determine promising therapeutic targets involved in the progression of the disease.

We recently showed that human recombinant TNF-α could induce inflammation in both bovine and human NP cells21, which is in accordance with other studies in the field confirming that TNF-α can be used for inflammation simulation in IVD cells22,23. In the present study, a dose of 100 ng TNF-α per IVD was used to induce inflammation. This dose showed effective induction of inflammatory markers when applied in combination with degenerative loading and limited nutrition15,20. In a recent study using TNF-α as the sole initiation factor of IVD degeneration, a threshold of 100 ng TNF-α / cm3 disc volume has been determined as an effective dose for the induction of inflammatory and degenerative changes in the IVD21. It is suggested that the TNF-α dose used to induce inflammation should be normalized to the volume of the disc for reproducible effects. Furthermore, it should be ensured that there is a good distribution of the injection material in the IVD and that this injection will be adequately reproducible in subsequent experiments. As injection pressure may vary between individuals, there might be different distributions of the material among the same study groups in different experiments. One approach we chose to examine the equal distribution was using PBS diluted trypan blue injections. It is recommended to standardize the injection technique, for example, with injection pumps and predefined and reproducible injection rates. As shown previously, one single needle puncture with 22-gauge, 25-gauge, or 30-gauge needles into the IVD did not cause an effect that interacted with study outcomes20,21,24,25. It is recommended to consider the disc size for the volume of the substance to be injected and for the needle size used for injection. Further, it is recommended to use a single injection to avoid inducing potential degenerative effects caused by multiple annular injections21,26.

Some limitations of the present model need to be addressed. The loading of the IVDs requires access to bioreactors, which are currently not widely available in many labs working on IDD. However, the need for preclinical IVD degeneration models is rising. Organ culture models bring ethical benefits of reducing the need for animal models, and the one-time investment on bioreactor costs could be affordable considering the reproducibility of the degenerative stimulation, and the reductions in the costs associated with animal experiments. Nevertheless, some in vivo interactions, such as the role of the immune system, cannot be simulated with the provided organ culture model. Moreover, the measurement of nerve signals and the evaluation of pain that would be possible in animal models can currently not be considered with the current model. Some concerns were raised whether the mechanical properties of tail IVDs could be comparable with human IVDs as the upright spine position is unique in humans28. Anatomical and molecular properties of bovine tail IVDs, such as cell density, lack of notochordal cells, biochemical composition29,30, and mechanical properties of bovine caudal IVDs, such as range of motion in flexion, extension, torsion, and bending31 are very similar to human IVDs. Notably, human IVDs gain more and more attention recently for organ culture models28. Human cadaveric IVDs in ex vivo models are considered highly efficient as they can avoid species differences which are more clinically relevant32. In contrast to bovine IVD tails obtained from the abattoirs, this would require transplantation of human IVDs 24 h post mortem and, thus, ethical approval following local organ transplantation laws28. The present method can also be easily adapted to other species.

One major advantage of the technique compared to other methods of ex vivo cultures is the combination of intradiscal injection, pathological medium conditions, and detrimental loading to simulate the early stage of degenerative discs better. Walter et al.23 used TNF-alpha in the medium of dynamically loaded bovine IVDs instead of injection into the IVDs and showed increased transport of TNF-alpha from the medium into the nucleus pulposus compared to the annulus fibrosus, which is in accordance with our results. As we aimed to simulate the early stages of IDD, which occurs at the cellular level without major disruptions of the discs architecture12, we chose the TNF-alpha concentrations based on previous organ culture studies using TNF-alpha in the medium to simulate the early stages of IDD12,22,23. The use of other inflammatory stimulants and higher concentrations of TNF-alpha could be tested to simulate the desired degenerative disc state depending on the study question. Higher concentrations of TNF-alpha may better compensate the lack of systemic immune regulatory feedbacks present during disc degeneration as proposed by Ponnappan et al.12 The use of detrimental medium conditions with low-glucose was based on previous work showing that nutritionally limiting media and exposure to TNF-alpha mimics molecular change characteristics which are available in early disc degeneration state12, 27. Thus, the approach combines the evidence provided by previous studies in one ex vivo organ culture model of early degenerative disc disease.

This protocol can be further improved in several ways. The duration and extent of the loading and free-swelling period can be chosen based on the desired study plan. Long-term effects of inflammatory or degenerative stimulations on disc degeneration are of high clinical interest and can be accomplished with the current protocol. We used only selected genes considered highly relevant for the early state of IDD11. Additional validation of this model could include a widened assessment of genes and proteins, such as omics approaches. Consequently, other inflammatory factors could be investigated in combination with the degenerative loading, depending on the desired degenerative state. For example, lipopolysaccharide injections have been shown to stimulate inflammation in the IVD33. A comparison of different inflammatory stimulants can be accomplished with the present protocol to find the most appropriate inflammatory stimulant for the desired study question. We have evaluated changes of selected inflammatory markers (IL-6, IL-8), anabolic markers (aggrecan, collagen), and catabolic markers (matrix metallopeptidases, a disintegrin and metalloproteinases with thrombospondin motifs) with the present protocol20. As the whole gene expression profile might change, future examinations could include next-generation RNA sequencing techniques to determine novel biomarkers for disc degeneration diagnostics and therapeutic targets for early biological intervention. Furthermore, other methodologies, such as histology, immunohistochemical staining, biochemical measurements of extracellular matrix components (such as glycosaminoglycans, GAGs), and dynamic compressive tests can be performed to further analyze the biological, biochemical, and biomechanical properties of IVDs with the present model. Another possible analytical way would be to separately analyze the impact on outer AF and NP tissue by using bCol1a1, Col1a2, CD146, SM22α, and MKX as gene expression markers for the outer AF34,35. The Spine Research Interest Group at the 2014 Annual ORS Meeting in New Orleans recommended following healthy NP phenotypic markers: HIF-1alpha, GLUT-1, aggrecan/collagen II ratio >20, Shh, Brachyury, KRT18/19, CA12, and CD2436. The NP marker genes bBrachyury/T and bSecreted frizzled-related protein 2 were the most convincing separating NP from inner and outer AF tissue in the bovine IVD34. Furthermore, the sGAG content of the NP was reported to be significantly higher compared to the outer AF34.

In conclusion, this novel proinflammatory and degenerative IVD organ culture model provides relevant conditions to simulate early-stage IDD in a highly relevant 3D microenvironment. Certainly, the present protocol can be further modified according to the investigator's objectives. Furthermore, our model is able to reduce the number of needed study animals and thus totally reflects the 3R principles of reduce, replace, refine.

Subscription Required. Please recommend JoVE to your librarian.

Disclosures

The authors have nothing to disclose.

Acknowledgments

This work was supported by AO Foundation and AOSpine International. Babak Saravi received fellowship support from the German Spine Foundation and the German Osteoarthritis Foundation. Gernot Lang was supported by the Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg, Germany.

Materials

Name Company Catalog Number Comments
1-Bromo-3-chloropropane(BCP) Sigma-Aldrich, St. Louis, USA B9673
Ascorbate-2-phosphate Sigma-Aldrich, St. Louis, USA A8960
Band saw Exakt Apparatebau, Norderstedt, Germany model 30/833
Betadine Munndipharma, Frankfurt, Germany
Bovine IL-8 Do.it-Yourself ELISA Kingfisher Biotech, St. Paul, USA DIY1028B-003
Corning ITS Premix Corning Inc., New York, USA 354350
DMEM high glucose Gibco by life technologies, Carlsbad, USA 10741574
DMEM low glucose Gibco by life technologies, Carlsbad, USA 11564446
Ethanol for molecular biology Sigma-Aldrich, St. Louis, USA 09-0851
Fetal Bovine Serum (FBS) Gibco by life technologies, Carlsbad, USA A4766801
Non-essential amino acid solution Gibco by life technologies, Carlsbad, USA 11140050
Penicillin/Streptomycin(P/S) gibco by life technologies, Carlsbad, USA 11548876
Phosphate Buffer Solution, tablet Sigma-Aldrich, St. Louis, USA P4417
Pronase Sigma-Aldrich, St. Louis, USA 10165921001
Primocin InvivoGen, Sandiego, USA ant-pm-05
Pulsavac Jet Lavage System Zimmer, IN,USA
TissueLyser II Quiagen, Venlo, Netherlands 85300
Streptavidinn-HRP Kingfisher Biotech, St. Paul, USA AR0068-001
Superscript VILO Invitrogen by life Technologies, Carlsbad, USA 10704274
cDNA Synthesis Kit Applied Biosystems by life technologies 10400745
TaqMan Universal Master Mix Applied Biosystems by life technologies
TNF-alpha, recombinant human protein R&D systems, Minnesota, USA 210-TA-005
TRI Reagent Molecular Research Center, Cincinnati, USA TR 118
Tris-EDTA buffer solution sigma-Aldrich, St. Louis, USA 93283
Gene bIL-6 Applied Biosystems by life technologies Custom made probes Primer fw (5′–3′) TTC CAA AAA TGG AGG AAA AGG A
Primer rev (5′–3′) TCC AGA AGA CCA GCA GTG GTT
Probe (5′FAM/3′TAMRA) CTT CCA ATC TGG GTT CAA TCA GGC GATT
Gene bIL8 Applied Biosystems by life technologies Bt03211906_m1
Gene bTNF-alpha Applied Biosystems by life technologies Custom made probes Primer fw (5′–3′) CCT CTT CTC AAG CCT CAA GTA ACA A
Primer rev (5′–3′) GAG CTG CCC CGG AGA GTT
Probe (5′FAM/3′TAMRA) ATG TCG GCT ACA ACG TGG GCT ACC G
GENE bIL1beta Applied Biosystems by life technologies Custom made probes Primer fw (5′–3′) TTA CTA CAG TGA CGA GAA TGA GCT GTT
Primer rev (5′–3′) GGT CCA GGT GTT GGA TGC A
Probe (5′FAM/3′TAMRA) CTC TTC ATC TGT TTA GGG TCA TCA GCC TCA A
RPLP0 Applied Biosystems by life technologies Bt03218086_m1

DOWNLOAD MATERIALS LIST

References

  1. Vos, T., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 390, (10100), 1211-1259 (2017).
  2. Hoy, D., et al. Measuring the global burden of low back pain. Best Practice & Research Clinical Rheumatology. 24, (2), 155-165 (2010).
  3. Thiese, M. S., et al. Prevalence of low back pain by anatomic location and intensity in an occupational population. BMC Musculoskeletal Disorders. 15, (1), 283 (2014).
  4. Katz, J. N. Lumbar Disc Disorders and Low-Back Pain: Socioeconomic Factors and Consequences. The Journal of Bone and Joint Surgery (American). 88, suppl_2 21 (2006).
  5. Vlaeyen, J. W. S., et al. Low back pain. Nature Reviews Disease Primers. 4, (1), 52 (2018).
  6. Khan, A. N., et al. Inflammatory biomarkers of low back pain and disc degeneration: a review: Biomarkers of disc degeneration and back pain. Annals of the New York Academy of Sciences. 1410, (1), 68-84 (2017).
  7. Kim, H. S., Wu, P. H., Jang, I. T. Lumbar Degenerative Disease Part 1: Anatomy and Pathophysiology of Intervertebral Discogenic Pain and Radiofrequency Ablation of Basivertebral and Sinuvertebral Nerve Treatment for Chronic Discogenic Back Pain: A Prospective Case Series and Review of Literature. International Journal of Molecular Sciences. 21, (4), 1483 (2020).
  8. Adams, M. A., Roughley, P. J. What is Intervertebral Disc Degeneration, and What Causes It. Spine. 31, (18), 2151-2161 (2006).
  9. Wu, P. H., Kim, H. S., Jang, I. T. Intervertebral Disc Diseases Part 2: A Review of the Current Diagnostic and Treatment Strategies for Intervertebral Disc Disease. International Journal of Molecular Sciences. 21, (6), 2135 (2020).
  10. Lurie, J. D., et al. Surgical Versus Nonoperative Treatment for Lumbar Disc Herniation: Eight-Year Results for the Spine Patient Outcomes Research Trial. Spine. 39, (1), 3-16 (2014).
  11. Risbud, M. V., Shapiro, I. M. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nature Reviews Rheumatology. 10, (1), 44-56 (2014).
  12. Ponnappan, R. K., et al. An organ culture system to model early degenerative changes of the intervertebral disc. Arthritis Research & Therapy. 13, (5), 171 (2011).
  13. O'Connell, G. D., Vresilovic, E. J., Elliott, D. M. Comparison of Animals Used in Disc Research to Human Lumbar Disc Geometry. Spine. 32, (3), 328-333 (2007).
  14. Stannard, J. T., et al. Development of a whole organ culture model for intervertebral disc disease. Journal of Orthopaedic Translation. 5, 1-8 (2016).
  15. Li, Z., et al. Preclinical ex-vivo Testing of Anti-inflammatory Drugs in a Bovine Intervertebral Degenerative Disc Model. Frontiers in Bioengineering and Biotechnology. 8, 583 (2020).
  16. Li, Z., et al. Development of an ex vivo cavity model to study repair strategies in loaded intervertebral discs. European Spine Journal. 25, (9), 2898-2908 (2016).
  17. Kazezian, Z., Li, Z., Alini, M., Grad, S., Pandit, A. Injectable hyaluronic acid down-regulates interferon signaling molecules, IGFBP3 and IFIT3 in the bovine intervertebral disc. Acta Biomaterialia. 52, 118-129 (2017).
  18. Caprez, S., Menzel, U., Li, Z., Grad, S., Alini, M., Peroglio, M. Isolation of high-quality RNA from intervertebral disc tissue via pronase predigestion and tissue pulverization. JOR Spine. 1, (2), 1017 (2018).
  19. Lopa, S., Ceriani, C., Cecchinato, R., Zagra, L., Moretti, M., Colombini, A. Stability of housekeeping genes in human intervertebral disc, endplate and articular cartilage cells in multiple conditions for reliable transcriptional analysis. European Cells & Materials. 31, 395-406 (2016).
  20. Lang, G., et al. An intervertebral disc whole organ culture system to investigate proinflammatory and degenerative disc disease condition. Journal of Tissue Engineering and Regenerative Medicine. 12, (4), 2051-2061 (2018).
  21. Du, J., et al. Proinflammatory intervertebral disc cell and organ culture models induced by tumor necrosis factor alpha. JOR Spine. 3, 1104 (2020).
  22. Purmessur, D., Walter, B. A., Roughley, P. J., Laudier, D. M., Hecht, A. C., Iatridis, J. A role for TNFα in intervertebral disc degeneration: A non-recoverable catabolic shift. Biochemical and Biophysical Research Communications. 433, (1), 151-156 (2013).
  23. Walter, B. A., Likhitpanichkul, M., Illien-Junger, S., Roughley, P. J., Hecht, A. C., Iatridis, J. C. TNFα Transport Induced by Dynamic Loading Alters Biomechanics of Intact Intervertebral Discs. PLOS One. 10, (3), 0118358 (2015).
  24. Gullbrand, S. E., et al. A large animal model that recapitulates the spectrum of human intervertebral disc degeneration. Osteoarthritis and Cartilage. 25, (1), 146-156 (2017).
  25. Willems, N., et al. Safety of intradiscal injection and biocompatibility of polyester amide microspheres in a canine model predisposed to intervertebral disc degeneration: intradiscal application of pea microspheres. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 105, (4), 707-714 (2017).
  26. Michalek, A. J., Buckley, M. R., Bonassar, L. J., Cohen, I., Iatridis, J. C. The effects of needle puncture injury on microscale shear strain in the intervertebral disc annulus fibrosus. The Spine Journal. 10, (12), 1098-1105 (2010).
  27. Illien-Jünger, S., et al. The combined effects of limited nutrition and high-frequency loading on intervertebral discs with endplates. Spine. 35, (19), 1744-1752 (2010).
  28. Gantenbein, B., et al. Organ culture bioreactors--platforms to study human intervertebral disc degeneration and regenerative therapy. Current Stem Cell Research & Therapy. 10, (4), 339-352 (2015).
  29. Boubriak, O. A., Watson, N., Sivan, S. S., Stubbens, N., Urban, J. P. G. Factors regulating viable cell density in the intervertebral disc: blood supply in relation to disc height. Journal of Anatomy. 222, (3), 341-348 (2013).
  30. Maroudas, A., Stockwell, R. A., Nachemson, A., Urban, J. Factors involved in the nutrition of the human lumbar intervertebral disc: cellularity and diffusion of glucose in vitro. Journal of Anatomy. 120, Pt 1 113-130 (1975).
  31. Beckstein, J. C., Sen, S., Schaer, T. P., Vresilovic, E. J., Elliott, D. M. Comparison of Animal Discs Used in Disc Research to Human Lumbar Disc: Axial Compression Mechanics and Glycosaminoglycan Content. Spine. 33, (6), 166-173 (2008).
  32. Walter, B. A., Illien-Jünger, S., Nasser, P. R., Hecht, A. C., Iatridis, J. C. Development and validation of a bioreactor system for dynamic loading and mechanical characterization of whole human intervertebral discs in organ culture. Journal of Biomechanics. 47, (9), 2095-2101 (2014).
  33. Rajan, N. E., et al. Toll-Like Receptor 4 (TLR4) Expression and Stimulation in a Model of Intervertebral Disc Inflammation and Degeneration. Spine. 38, (16), 1343-1351 (2013).
  34. vanden Akker, G. G., Rorije, A. J., Davidson, E. N. B., vander Kraan, P. M. Phenotypic marker genes distinguish inner and outer annulus fibrosus from nucleus pulposus tissue in the bovine intervertebral disc. Osteoarthritis and Cartilage. 25, 402 (2017).
  35. Du, J., et al. Functional cell phenotype induction with TGF-β1 and collagen-polyurethane scaffold for annulus fibrosus rupture repair. European Cells & Materials. 39, 1-17 (2020).
  36. Risbud, M. V., et al. Defining the phenotype of young healthy nucleus pulposus cells: recommendations of the Spine Research Interest Group at the 2014 annual ORS meeting. Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society. 33, (3), 283-293 (2015).
A Proinflammatory, Degenerative Organ Culture Model to Simulate Early-Stage Intervertebral Disc Disease.
Play Video
PDF DOI DOWNLOAD MATERIALS LIST

Cite this Article

Saravi, B., Lang, G., Grad, S., Alini, M., Richards, R. G., Schmal, H., Südkamp, N., Li, Z. A Proinflammatory, Degenerative Organ Culture Model to Simulate Early-Stage Intervertebral Disc Disease.. J. Vis. Exp. (168), e62100, doi:10.3791/62100 (2021).More

Saravi, B., Lang, G., Grad, S., Alini, M., Richards, R. G., Schmal, H., Südkamp, N., Li, Z. A Proinflammatory, Degenerative Organ Culture Model to Simulate Early-Stage Intervertebral Disc Disease.. J. Vis. Exp. (168), e62100, doi:10.3791/62100 (2021).

Less
Copy Citation Download Citation Reprints and Permissions
View Video

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter